The 2 companies say that they will focus on biosimilars of originator products that will face patent expiry in 2025 to 2030.
STADA and Xbrane Biopharma recently announced that they have expanded their biosimilar collaboration to evaluate potential collaboration on additional products.
The 2 companies say that they will focus on biosimilars of originator products that will face patent expiry in 2025 to 2030. Two programs have been identified as targets of the collaboration: a certolizumab pegol product referencing Cimzia, and a nivolumab product referencing Opdivo. Both of these proposed products are in preclinical development.
For these 2 products, up to the time of the initiation of clinical trials, the companies will evaluate and negotiate potential development and commercialization agreement. During this period, Xbrane has given STADA a right of first refusal to license the 2 products in Europe.
The companies also plan to evaluate potential collaborations on additional biosimilars in the future.
Currently, the 2 drug makers have entered into a development agreement for a ranibizumab biosimilar referencing Lucentis. Under the terms of the agreement, both companies will contribute equally to development expenses, and will share the profits from commercialization in an even split.
STADA last year announced its intention to increase its presence in biosimilars by becoming the majority shareholder in another company, Bioceuticals, which is responsible for the production of erythropoietin. Previously, the company issued sales licenses to third parties such as Stadapharma, a subsidiary of STADA, for the marketing of the biosimilar epoetin zeta (sold in the European Union under brand name Silapo).
The epoetin biosimilar is also sold under an agreement between STADA and Hospira, a Pfizer subsidiary, under the brand name Retacrit.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.